Resultados de procura - Ruth Plummer

A hybrid machine learning approach for the personalized prognostication of aggressive skin cancers por Tom W. Andrew, Mogdad Alrawi, Ruth Plummer, Nick Reynolds, Vern Sondak, Isaac Brownell, Penny E. Lovat, Aidan Rose, Sophia Z. Shalhout

Ligazón do recurso

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study proto... por Sarah Johnson, Geoff Shenton, Ruth Plummer, Joshua Savage, Gareth J Veal, Julie Irving, Lucinda Billingham, Pamela Kearns, Daniel Slade, Tobias Menne, Britta Vormoor, Josef Vormoor

Ligazón do recurso

Targeting the DNA double strand break repair machinery in prostate cancer. por Fadhel S Shaheen, Pawel Znojek, Ann Fisher, Martin Webster, Ruth Plummer, Luke Gaughan, Graeme C M Smith, Hing Y Leung, Nicola J Curtin, Craig N Robson

Ligazón do recurso

Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma por Tom W. Andrew, Marc Combalia, Carlos Hernandez, Sydney Grant, Gyorgy Paragh, Susanna Puig, Grant Mc Arthur, Grant Richardson, Phil Sloan, Sophia Z. Shalhout, Ruth Plummer, Penny E. Lovat

Ligazón do recurso

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal can... por David Cunningham, Paul Ross, Ruth Plummer, Joshua Savage, Gary Middleton, Mark Saunders, Daniel Palmer, Anne Thomas, Lucinda Billingham, Sally Clive, Vicky Coyle, John Bridgewater, Phillipe Taniere, Charlotte Gaskell

Ligazón do recurso

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study por Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu

Ligazón do recurso

Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT por Vicky Coyle, Caroline Forde, Richard Adams, Ashley Agus, Rosemary Barnes, Ian Chau, Mike Clarke, Annmarie Doran, Margaret Grayson, Danny McAuley, Cliona McDowell, Glenn Phair, Ruth Plummer, Dawn Storey, Anne Thomas, Richard Wilson, Ronan McMullan

Ligazón do recurso

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors por Jatinder Kaur Mukker, Timothy A. Yap, Anthony W. Tolcher, Johann S. deBono, Ruth Plummer, Gary Grosser, Christoph vanAmsterdam, Hanno Schieferstein, Han Witjes, Paul Matthias Diderichsen, Axel Krebs‐Brown, Wei Gao, Rainer Strotmann, Zoltan Szucs, Ioannis Gounaris, Karthik Venkatakrishnan

Ligazón do recurso

Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study por Abigail Gault, Linda Hogarth, Kristian C Williams, Alastair Greystoke, Neil Rajan, Ally Speight, Christopher A Lamb, Alison Bridgewood, Lisa-Jayne Brown-Schofield, Fiona Rayner, John D Isaacs, Jérémie Nsengimana, Christopher J Stewart, Amy E Anderson, Ruth Plummer, Arthur G Pratt

Ligazón do recurso

A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma por Juanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, Paul M. Clement, Thomas R. Jeffry Evans, Heinz Läubli, Patrick Roth, Rebecca Kristeleit, Lucy Brazil, Ghazaleh Tabatabai, Antje Wick, Benjamin Wunderlich, Kirk Beebe, Joel Robert Eisner, Heidi Lane, Marc Engelhardt, Thomas Kaindl, Peter Hau, Thomas Hundsberger, Joachim Steinbach

Ligazón do recurso

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer por Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer

Ligazón do recurso

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase por Sarah E. Fordham, Helen J. Blair, Claire J. Elstob, Ruth Plummer, Yvette Drew, Nicola J. Curtin, Olaf Heidenreich, Deepali Pal, David Jamieson, Catherine Park, John Pollard, Scott Fields, Paul Milne, Graham H. Jackson, Helen J. Marr, Tobias Menne, Gail L. Jones, James M. Allan

Ligazón do recurso

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (... por Benjamin A Fisher, Arthur Pratt, Andrew Filer, Yin Wu, Kulveer Mankia, Michele Bombardieri, Ernest Wong, Miranda Payne, Tamir Malley, Ruth Plummer, Andrew P Cope, Anna Rowe, Manpreet Wilkhu, Shirish Dubey, Tim Blake, Emily Williams, Victoria Homer, Elliot Turner, Chris Hodson, Andrew Allard, Owen Moore, Michael Tilby, Tania Tillett, Lalit Pallan

Ligazón do recurso

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial por Rebecca J. Lee, Dominic G. Rothwell, Nigel Smith, Shien Chow, Juan Delgado-SanMartin, Hitesh Mistry, Yvonne Sylvestre, Shih-Chieh Chiang, Harry Clarke, Gabriela Gremel, Avinash Gupta, Kimberley Hockenhull, Noel Kelso, Rohit Kochhar, Damian Mullan, Ruth Plummer, Patricio Serra, Heather Shaw, Holly Summersgill, Samra Turajlic, Florent Mouliere, Richard Marais, Caroline Dive, Paul Lorigan

Ligazón do recurso

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors por Ruth Plummer, Mikael H. Sodergren, Rose Hodgson, Bríd M. Ryan, Nina Raulf, Joanna P. Nicholls, Vikash Reebye, Jon Voutila, Laura Sinigaglia, Tim Meyer, David J. Pinato, Debashis Sarker, Bristi Basu, Sarah Blagden, Natalie Cook, Thomas R. Jeffrey Evans, Jeffrey Yachnin, Cheng E. Chee, Daneng Li, Anthony El-Khoueiry, Maria Diab, Kai-Wen Huang, Madhava Pai, Duncan Spalding, Thomas Talbot, Marcus S. Noel, Bridget Keenan, Devalingam Mahalingam, Min-Sun Song, Mélanie Grosso, Denis Arnaud, Aurelie Auguste, Dimitris Zacharoulis, Jan Storkholm, Iain McNeish, Robert Habib, John J. Rossi, Nagy A. Habib

Ligazón do recurso

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort stu... por Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty

Ligazón do recurso